Study details
Enrolling now
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Mayo Clinic
NCT IDNCT04605913ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
40
Study length
about 3.9 years
Ages
18+
Locations
1 site in FL
About this study
This trial is testing a new treatment for people with metastatic pancreatic cancer. The treatment involves combining nab-paclitaxel, cisplatin, gemcitabine, and tumor treatment fields (TTF). This is a Phase 1/2 trial that will last about 1430 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Modified GCN+TTF treatment
PhasePhase 1/Phase 2
Primary goalSafety of (m)-GCN+TTF
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Safety of (m)-GCN+TTF
Secondary: Overall Response Rate (ORR), Overall Survival (OS), Progression-free Survival (PFS), Quality of Life - EORTC QLQ-C30, Time to Progression (TTP)
Body systems
Oncology